Chronic Hepatitis C and Insulin Resistance.
10.4166/kjg.2012.59.4.268
- Author:
Woo Jin CHUNG
1
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. chung50@dsmc.or.kr
- Publication Type:Review ; English Abstract
- Keywords:
Chronic hepatitis;
Hepatitis C virus;
Insulin resistance
- MeSH:
Antiviral Agents/therapeutic use;
Diabetes Mellitus, Type 2/complications/drug therapy/metabolism;
Genotype;
Hepatitis C, Chronic/*drug therapy/etiology/metabolism;
Humans;
Hypoglycemic Agents/therapeutic use;
Insulin/therapeutic use;
*Insulin Resistance;
Liver Cirrhosis/etiology;
Liver Neoplasms/etiology;
Sulfonylurea Compounds/therapeutic use
- From:The Korean Journal of Gastroenterology
2012;59(4):268-274
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Insulin resistance is frequently associated with chronic liver disease, and the interaction between hepatitis C virus (HCV) infection and insulin resistance is a major public health issue, bound to increase in the near term. Because of their potential synergism on liver disease severity, a better understanding of the clinical consequences of the relationship between HCV infection and insulin resistance is needed. This translates into accelerated liver disease progression, reduced response to anti-viral agents and, in susceptible individuals, increased risk of developing type 2 diabetes. HCV may also cause hepatic steatosis, especially in patients infected with genotype 3, although the clinical impact of viral steatosis is debated. Little is known regarding the effect of anti-diabetic agents on HCV infection, and a possible association between use of exogenous insulin or a sulfonylurea agents and the development of hepatocellular carcinoma has recently been reported. Thus, modified lifestyle and pharmacological modalities are urgently warranted in chronic hepatitis C with metabolic alterations.
